Sørensen Sissel Brandt Toft, Fuglsang Cecilia H, Horváth-Puhó Erzsébet
Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.
J Thromb Thrombolysis. 2025 Sep 4. doi: 10.1007/s11239-025-03175-2.
Atopic dermatitis is a risk factor for venous thromboembolism which may be the first manifestation of occult cancer. We examined whether a venous thromboembolism in patients with atopic dermatitis is a marker of occult cancer. We used Danish health registries to conduct this population-based cohort study. Patients with a first-time diagnosis of venous thromboembolism and a history of atopic dermatitis were identified from the Danish National Patients Registry from 1980 through 2022. We calculated the absolute risk of cancer treating death as a competing event. As a measure of relative risk, we calculated standardized incidence ratios (SIRs) for cancer among patients with venous thromboembolism and atopic dermatitis and compared the observed cancer incidence to that of the general Danish population. We identified 582 patients with a first venous thromboembolism diagnosis and a history of atopic dermatitis. During the first year of follow-up, the absolute risk of overall cancer was 1.7%, corresponding to an SIR of 2.90 (95% confidence interval [CI] 1.39-5.34). The overall SIR decreased to 1.12 (95% CI 0.74-1.62) during the subsequent years of follow-up. Although the risk estimates were imprecise, an elevated cancer risk following venous thromboembolism in patients with atopic dermatitis cannot be ruled out, particularly within the first year after venous thromboembolism, when compared to the cancer risk in the general population.
特应性皮炎是静脉血栓栓塞的一个危险因素,而静脉血栓栓塞可能是隐匿性癌症的首发表现。我们研究了特应性皮炎患者发生的静脉血栓栓塞是否为隐匿性癌症的一个标志物。我们利用丹麦健康登记系统开展了这项基于人群的队列研究。从丹麦国家患者登记系统中识别出1980年至2022年期间首次诊断为静脉血栓栓塞且有特应性皮炎病史的患者。我们将癌症治疗死亡作为竞争事件计算了患癌的绝对风险。作为相对风险的一种衡量指标,我们计算了静脉血栓栓塞和特应性皮炎患者的癌症标准化发病比(SIRs),并将观察到的癌症发病率与丹麦普通人群的发病率进行了比较。我们识别出582例首次诊断为静脉血栓栓塞且有特应性皮炎病史的患者。在随访的第一年,总体癌症的绝对风险为1.7%,对应的SIR为2.90(95%置信区间[CI] 1.39 - 5.34)。在随后的随访年份中,总体SIR降至1.12(95% CI 0.74 - 1.62)。尽管风险估计不精确,但与普通人群的癌症风险相比,不能排除特应性皮炎患者发生静脉血栓栓塞后癌症风险升高的情况,尤其是在静脉血栓栓塞后的第一年。